Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Bullboard Posts
Post by stockgurukingon Oct 03, 2012 12:30pm
306 Views
Post# 20442960

Perfect Storm Brewing

Perfect Storm Brewing

The timing for release of ICO's interim Phase II data this Fall could not be better with the NASDAQ Biotech index being at 14 year high:

-

https://www.stockwatch.com/Quote/Detail.aspx?action=go&symbol=$NBI&region=U&lookup=symbol&snapshot=default

-

And just today Sarepta (NASDAQ: SRPT) is up 160% and $24 after announcing positive Phase II data on their RNA-based technology for treatment of Duchenne Muscular Dystrophy.

-

Based on when the Phase II trial started and some major eye conferences occuring in November the countdown to interim data is likely 30 to 60 days.

Bullboard Posts